Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Oncofertility
  • Reduced price
The Triptans: Novel Drugs for Migraine

The Triptans: Novel Drugs for Migraine

9780192632142
1,877.85 zł
1,690.06 zł Save 187.79 zł Tax included
Lowest price within 30 days before promotion: 1,690.06 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
A new era in the treatment of migraine headache arrived with development of a revolutionary class of drugs known as the triptans.The book describes the development of this class of drugs, starting with the discovery of sumatriptin, covers the pharmacology and the mechanisms of action of the full range of triptans, before comparing their clinical efficacy and tolerability. Each drug is described by the company who produces it and then reviewed, based on experimental and clinical evidence, by independent scientists.This comprehensive review will provide clinicians with guidance on which triptan to select for which patient.The editors have gathered together the leading international experts to produce a book that will appeal to all neurologists and general physicians caring for headache patients as well as those with research interests in the field.
Product Details
OUP Oxford
82985
9780192632142
9780192632142

Data sheet

Publication date
2001
Issue number
1
Cover
hard cover
Pages count
358
Dimensions (mm)
172 x 247
Weight (g)
813
  • Section I - Background and early development; The discovery of sumatriptan and a new class of drugs for the acute treatment of migraine; 5-HT receptors in brain and vasculature; Structural and operational diversity of Serotonin receptors. Potential relevance to migraine pathophysiology and treatment; Characterisation of 5-HT1 receptor expression in human vasculature; 5-HT1B and 5-HT1D receptor immunoreactivity colocalize with sensory neurotransmitters in the human trigeminal ganglion; Upregulation of 5-HT1B/1D receptors during organ culture of cerebral arteries; Background and early development - discussion summary; Section II - Pharmacology of the triptans; Clinical pharmacokinetics of the triptans:what are the important clinical issues?; Pharmacodynamics of triptans; Characteristics of different routes of administration; Encapsulation of sumatriptan does not delay its absorption; Synergism of 5-HT1 and 5-HT2 receptors in sumatriptan-induced vasocontractile response in rabbit common carotid artery; Role of 5-HT1B and 5HT1D receptors in sumatriptan mediated vasocontractile response in rabbit common carotid artery; Comparison of triptan induced contractions in human cerebral vs coronary arteries; Pharmacological analysis of cotractile effects of eletriptan and sumatriptan on human isolated blood vessels; Pharmacology of the triptans: discussion summary; Section III - Antimigraine actions of the triptans; The importance of vasoconstriction in the mechanism of the antimigraine action of the triptans; Inhibition of neurogenic inflammation is most important; Central nervous system effects are most important; Do we really understand how triptans work?; The relevance of hepatic intrinsic clearance and brain penetration on the doses used for 5-HT agonists (triptans) in the treatment of migraine; In vivo serotonergic effects and extracellular brain levels of centrally and systemically administered eletriptan, zolmitriptan and sumatriptan; Regulation of capsaicin-evoked CGRP release from rat dural sensory neurones in vitro; Arterial distensibility in ergotamine and sumatriptan abuse; Anti migraine actions of the triptans: discussion summary; Section IV - Clinical efficacy and tolerability of the triptans; Sumatriptan: looking back and looking forward; Zolmitriptan offers doctor and patient choices for effective treatment of migraine; Rizatriptan: clinical update; Evidence against tight correlation between chest oppressive symptoms and ischaemic coronary changes after subcutaneous sumatriptan injection; Alteration in cluster headache during subcutaneous administration of sumatriptan; Efficacy and tolerability of rizatriptan 10mg in migraine: experience with 70527 patient episodes; Consistency of pain relief over multiple migraine attacks following treatment with rizatriptan; Naratriptan: the gentle triptan; Experience with eletriptan (RelpaxTM); Almotriptan; Frovatriptan: simplifying clinical practice in migraine; The cardiovascular safety of frovatriptan in patients at high risk of or with known coronary artery disease during a migraine attack; Lack of clinically significant interactions between frovatriptan and ergotamine, propranolol or moclobemide; Frovatriptan pharmocokinetics are unaffected during a migraine attack; Clinical efficacy and tolerability of the triptans: discussion summary; Section V - The triptans in clinical practice; Acute management of migraine: clinical trials of triptans versus other agents; Which triptans for which patient?; The Framig 99 survey III: therapeutical behaviour of migraineurs; Migraine in France in 2000: therapeutical data; The triptan threshold score: a score tohelp patients identify the best moment to take the triptan; Triptan plus NSAID with long half life: increase of efficacy and reduction of headache recurrence in acute migraine; Comparison of the triptans with other drugs in the development of drug-induced headache; An epidemiological study on the differences between sumatriptan and ergotamine overuse; Overuse of new 5-HT agonists (zolmitriptan and naratriptan) in migraine patients: clinical features; The triptans in clinical practice: discussion summary;
Comments (0)

  • Frequently purchased together

    No products available